Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axonics, Inc. stock logo
AXNX
Axonics
$66.64
+0.3%
$67.97
$47.59
$69.68
$3.40B0.561.27 million shs396,114 shs
Haemonetics Co. stock logo
HAE
Haemonetics
$86.23
+1.4%
$79.71
$70.74
$95.26
$4.38B0.36448,965 shs238,822 shs
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$74.03
-0.2%
$74.76
$62.58
$85.62
$4.30B0.89493,296 shs248,079 shs
Inari Medical, Inc. stock logo
NARI
Inari Medical
$38.18
+2.9%
$46.08
$36.73
$71.85
$2.21B0.841.14 million shs1.37 million shs
NuVasive, Inc. stock logo
NUVA
NuVasive
$39.75
$39.64
$35.17
$49.53
$2.08B1.071.16 million shsN/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axonics, Inc. stock logo
AXNX
Axonics
+0.26%-0.83%-3.04%-2.36%+14.62%
Haemonetics Co. stock logo
HAE
Haemonetics
+1.36%+1.59%+5.16%+6.14%+3.72%
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
-0.20%+3.52%+1.70%-5.37%-5.22%
Inari Medical, Inc. stock logo
NARI
Inari Medical
+2.88%-1.34%-9.93%-32.15%-43.36%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.00%0.00%0.00%0.00%-6.82%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axonics, Inc. stock logo
AXNX
Axonics
3.1575 of 5 stars
1.22.00.04.12.72.51.9
Haemonetics Co. stock logo
HAE
Haemonetics
4.4038 of 5 stars
2.34.00.04.33.31.72.5
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
4.7996 of 5 stars
3.44.00.03.82.82.52.5
Inari Medical, Inc. stock logo
NARI
Inari Medical
2.1912 of 5 stars
3.32.00.00.01.93.30.6
NuVasive, Inc. stock logo
NUVA
NuVasive
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axonics, Inc. stock logo
AXNX
Axonics
2.38
Hold$70.736.13% Upside
Haemonetics Co. stock logo
HAE
Haemonetics
2.50
Moderate Buy$104.6721.38% Upside
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
2.89
Moderate Buy$92.5024.95% Upside
Inari Medical, Inc. stock logo
NARI
Inari Medical
2.67
Moderate Buy$73.7193.07% Upside
NuVasive, Inc. stock logo
NUVA
NuVasive
2.50
Moderate Buy$51.3329.14% Upside

Current Analyst Ratings

Latest NUVA, HAE, NARI, AXNX, and MMSI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$98.00
4/12/2024
Haemonetics Co. stock logo
HAE
Haemonetics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$105.00
4/12/2024
Inari Medical, Inc. stock logo
NARI
Inari Medical
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
4/11/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$88.00
4/11/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$88.00
3/22/2024
Inari Medical, Inc. stock logo
NARI
Inari Medical
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$61.00 ➝ $52.00
3/6/2024
Inari Medical, Inc. stock logo
NARI
Inari Medical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00
2/29/2024
Axonics, Inc. stock logo
AXNX
Axonics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$71.00
2/29/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$82.00 ➝ $87.00
2/29/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$81.00 ➝ $88.00
2/29/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$96.00 ➝ $98.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axonics, Inc. stock logo
AXNX
Axonics
$366.38M9.28$0.13 per share529.18$12.59 per share5.29
Haemonetics Co. stock logo
HAE
Haemonetics
$1.17B3.75$5.13 per share16.81$16.22 per share5.32
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$1.26B3.42$4.88 per share15.18$20.81 per share3.56
Inari Medical, Inc. stock logo
NARI
Inari Medical
$493.63M4.48$0.09 per share430.17$8.07 per share4.73
NuVasive, Inc. stock logo
NUVA
NuVasive
$1.23B1.70$4.96 per share8.01$17.02 per share2.34

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axonics, Inc. stock logo
AXNX
Axonics
-$6.09M-$0.13N/A104.13N/A-1.66%-1.00%-0.90%5/6/2024 (Estimated)
Haemonetics Co. stock logo
HAE
Haemonetics
$115.40M$2.4635.0520.341.979.97%22.37%9.71%5/9/2024 (Confirmed)
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$94.41M$1.6245.7020.232.047.51%14.63%9.19%4/30/2024 (Confirmed)
Inari Medical, Inc. stock logo
NARI
Inari Medical
-$1.64M-$0.03N/A103.19N/A-0.33%1.23%0.97%4/30/2024 (Confirmed)
NuVasive, Inc. stock logo
NUVA
NuVasive
$40.41M$0.5079.5015.35N/A2.32%12.17%4.88%N/A

Latest NUVA, HAE, NARI, AXNX, and MMSI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Haemonetics Co. stock logo
HAE
Haemonetics
$0.88N/A-$0.88N/AN/AN/A  
4/30/2024N/A
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$0.70N/A-$0.70N/AN/AN/A  
4/30/2024N/A
Inari Medical, Inc. stock logo
NARI
Inari Medical
-$0.16N/A+$0.16N/AN/AN/A  
2/28/2024Q4 2023
Axonics, Inc. stock logo
AXNX
Axonics
$0.06$0.13+$0.07$0.13$107.33 million$109.70 million
2/28/2024Q4 2023
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$0.77$0.81+$0.04$1.15$320.66 million$324.52 million    
2/28/202412/31/2023
Inari Medical, Inc. stock logo
NARI
Inari Medical
$0.01-$0.08-$0.09$0.18$131.82 million$132.10 million    
2/8/202412/31/2023
Haemonetics Co. stock logo
HAE
Haemonetics
$0.94$1.04+$0.10$1.47$320.84 million$336.20 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axonics, Inc. stock logo
AXNX
Axonics
N/AN/AN/AN/AN/A
Haemonetics Co. stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
N/AN/AN/AN/AN/A
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/AN/AN/AN/AN/A
NuVasive, Inc. stock logo
NUVA
NuVasive
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axonics, Inc. stock logo
AXNX
Axonics
N/A
10.73
8.98
Haemonetics Co. stock logo
HAE
Haemonetics
0.91
2.92
1.76
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
0.68
5.45
3.95
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/A
3.09
2.52
NuVasive, Inc. stock logo
NUVA
NuVasive
0.50
1.25
0.65

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Axonics, Inc. stock logo
AXNX
Axonics
99.48%
Haemonetics Co. stock logo
HAE
Haemonetics
99.67%
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
99.66%
Inari Medical, Inc. stock logo
NARI
Inari Medical
90.98%
NuVasive, Inc. stock logo
NUVA
NuVasive
N/A

Insider Ownership

CompanyInsider Ownership
Axonics, Inc. stock logo
AXNX
Axonics
1.85%
Haemonetics Co. stock logo
HAE
Haemonetics
1.79%
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
3.70%
Inari Medical, Inc. stock logo
NARI
Inari Medical
10.60%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.53%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Axonics, Inc. stock logo
AXNX
Axonics
79751.00 million50.06 millionOptionable
Haemonetics Co. stock logo
HAE
Haemonetics
3,03450.79 million49.88 millionOptionable
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
6,95058.07 million55.92 millionOptionable
Inari Medical, Inc. stock logo
NARI
Inari Medical
1,30057.96 million51.82 millionOptionable
NuVasive, Inc. stock logo
NUVA
NuVasive
3,00052.45 million52.17 millionOptionable

NUVA, HAE, NARI, AXNX, and MMSI Headlines

SourceHeadline
Bone Void Fillers Market Size, Share, Key Players, Revenue, Demand, and Forecast to 2024 to 2032Bone Void Fillers Market Size, Share, Key Players, Revenue, Demand, and Forecast to 2024 to 2032
taiwannews.com.tw - April 19 at 1:56 AM
Regenerative Medicine Market Will Grow Nearly USD 194.9 Billion At A Rate Of 19.4% By 2032Regenerative Medicine Market Will Grow Nearly USD 194.9 Billion At A Rate Of 19.4% By 2032
pharmiweb.com - April 18 at 10:34 AM
SMAIO Publishes its 2023 Annual ResultsSMAIO Publishes its 2023 Annual Results
finance.yahoo.com - April 17 at 6:36 PM
This Week in Chancery Court: Poison Pill Ruling, NuVasiveThis Week in Chancery Court: Poison Pill Ruling, NuVasive
news.bloomberglaw.com - April 15 at 8:58 AM
Bone Grafting Screw Market Segmentation Analysis, Share, Trends, Size, Key Players, and Forecast 2024 to 2032Bone Grafting Screw Market Segmentation Analysis, Share, Trends, Size, Key Players, and Forecast 2024 to 2032
taiwannews.com.tw - April 12 at 7:59 AM
10 robots used in spine surgery10 robots used in spine surgery
beckersspine.com - April 10 at 6:27 PM
Global Polymeric Biomaterials Market 10 Year Forecast Report 2024-2034, with Company Profiles of the Top 10+ Major Market PlayersGlobal Polymeric Biomaterials Market 10 Year Forecast Report 2024-2034, with Company Profiles of the Top 10+ Major Market Players
finance.yahoo.com - April 9 at 10:20 AM
Accelus adds 2 leadersAccelus adds 2 leaders
beckersspine.com - April 3 at 3:20 PM
$14.3 Bn Spinal Implants Markets: Devices, Biologics, Stimulators, VCF, Spinal Decompression, Fusion, Non-Fusion - Global Forecast to 2028$14.3 Bn Spinal Implants Markets: Devices, Biologics, Stimulators, VCF, Spinal Decompression, Fusion, Non-Fusion - Global Forecast to 2028
finance.yahoo.com - April 3 at 10:19 AM
Spine Pain Market Expected to Reach US$12.47 Billion by 2033 with CAGR of 5%Spine Pain Market Expected to Reach US$12.47 Billion by 2033 with CAGR of 5%
fmiblog.com - April 2 at 2:16 PM
Globus Medical director sells $550K in stockGlobus Medical director sells $550K in stock
beckersspine.com - March 20 at 4:48 PM
Orthopedic Navigation Systems Market Will Increase USD 8.9 Billion By 2033 with 12.7% CAGROrthopedic Navigation Systems Market Will Increase USD 8.9 Billion By 2033 with 12.7% CAGR
pharmiweb.com - March 14 at 9:11 AM
Wrist Replacement Orthopedic Devices Market on Course to Achieve USD 618.9 Million by 2033 | Market.usWrist Replacement Orthopedic Devices Market on Course to Achieve USD 618.9 Million by 2033 | Market.us
pharmiweb.com - March 13 at 10:23 PM
Minimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarkets™Minimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarkets™
prnewswire.co.uk - March 13 at 10:23 PM
UK reinstates modified MAGEC X system for scoliosis treatmentsUK reinstates modified MAGEC X system for scoliosis treatments
msn.com - March 13 at 5:22 PM
Pediatric Orthopedic Implant Market Forecast Highlights 7.4% Growth Rate, Reaching USD 7.1 Billion by 2033Pediatric Orthopedic Implant Market Forecast Highlights 7.4% Growth Rate, Reaching USD 7.1 Billion by 2033
pharmiweb.com - March 12 at 4:16 PM
Orthobiologics Market Set to Reach $8.2 Billion by 2030, Viscosupplementation Segment Exhibiting Robust GrowthOrthobiologics Market Set to Reach $8.2 Billion by 2030, Viscosupplementation Segment Exhibiting Robust Growth
finance.yahoo.com - March 12 at 4:16 PM
Minimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarketsMinimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarkets
finanznachrichten.de - March 12 at 9:26 AM
NuVasive and Zimmer Biomet welcomed by MedAccred programNuVasive and Zimmer Biomet welcomed by MedAccred program
medicalplasticsnews.com - March 6 at 4:00 PM
J. Kurt Jacobus, Ph.D. Joins CurvaFix Board of DirectorsJ. Kurt Jacobus, Ph.D. Joins CurvaFix Board of Directors
finance.yahoo.com - March 5 at 2:31 PM
Crushed Great Ormond Street hospital patients left in limbo after treatment axedCrushed Great Ormond Street hospital patients 'left in limbo' after treatment axed
express.co.uk - February 22 at 9:18 AM
Great Ormond Street patient cant get MAGEC spine operationGreat Ormond Street patient can't get MAGEC spine operation
newsshopper.co.uk - February 22 at 12:47 AM
Q4 2023 Globus Medical Inc Earnings CallQ4 2023 Globus Medical Inc Earnings Call
uk.finance.yahoo.com - February 21 at 2:46 PM
Globus Medical: Hold Rating Affirmed Amidst Modest Growth Projections and Integration RisksGlobus Medical: Hold Rating Affirmed Amidst Modest Growth Projections and Integration Risks
markets.businessinsider.com - February 21 at 2:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Axonics logo

Axonics

NASDAQ:AXNX
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Haemonetics logo

Haemonetics

NYSE:HAE
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Merit Medical Systems logo

Merit Medical Systems

NASDAQ:MMSI
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Inari Medical logo

Inari Medical

NASDAQ:NARI
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
NuVasive logo

NuVasive

NASDAQ:NUVA
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.